Home
News
Create
Screeners
Insights
Dr Lalchandani Labs
9.
88
-9.88
(-100.00%)
Market Cap
₹8.60 Cr
PE Ratio
20.58
Industry
Healthcare Services
Buy
Sell
Company Performance:
1D
-100.00%
1M
-100.00%
6M
-100.00%
1Y
-100.00%
5Y
-100.00%
View Company Insights
Latest news about Dr Lalchandani Labs
Dr Lalchandani Labs Limited Submits Q4FY26 Compliance Certificate Under SEBI Regulation 74(5)
Apr 10, 2026
Dr Lalchandani Labs Limited filed its Q4FY26 compliance certificate under SEBI Regulation 74(5) on April 09, 2026, for the quarter ended March 31, 2026. The certificate, issued by registrar Cameo Corporate Services Limited, confirms proper processing of dematerialised securities, including verification, cancellation of physical certificates, and timely substitution of depositary names in the register of members.
Bandhan AMC Limited Declares Dividend with Record Date March 10, 2026
Mar 06, 2026
Anuraag Gambhir Acquires 15.05% Stake in Dr. Lalchandani Labs Through Rights Issue
Mar 05, 2026
Dr Lalchandani Labs Completes Rights Issue Allotment, Doubles Share Capital
Mar 02, 2026
Dr Lalchandani Labs Publishes Newspaper Notice for Rights Issue Extension
Feb 17, 2026
More news about Dr Lalchandani Labs
31
Jan 26
Dr Lalchandani Labs Limited Completes Rights Issue Material Dispatch for ₹433.20 Lakhs Offering
Dr Lalchandani Labs Limited has completed dispatch of rights issue material for its ₹433.20 lakhs offering of 43,32,000 equity shares at ₹10 per share in 1:1 ratio. The issue opens February 4, 2026 and closes February 20, 2026, with mandatory ASBA process for applications and dematerialised allotment only.
20
Jan 26
Dr Lalchandani Labs Approves ₹4.33 Crore Rights Issue with 1:1 Entitlement Ratio
Dr Lalchandani Labs Limited approved a rights issue of 43.32 lakh equity shares at ₹10 per share, totaling ₹4.33 crores. The 1:1 entitlement ratio allows existing shareholders to purchase one new share for every share held as of January 27, 2026 record date. The issue opens February 4, 2026 and closes February 20, 2026, potentially doubling outstanding shares to 86.65 lakh upon full subscription.
16
Jan 26
Dr Lalchandani Labs Receives BSE In-Principle Approval for Rights Issue
Dr Lalchandani Labs has received BSE in-principle approval for its proposed rights issue worth ₹433.31 lakhs through reference number LOD/Rights/RB/FIP/1544/2025-26 dated January 16, 2026. The approval permits the company to proceed with issuing fully paid-up equity shares with face value of ₹10 each to eligible shareholders, subject to compliance with statutory requirements and post-issue formalities.
05
Sept 25
Dr Lalchandani Labs Appoints New Independent Director and Expands Authorized Capital
Dr Lalchandani Labs Limited has announced key corporate developments following a board meeting. The company appointed Mr. Mohan Lal Gandhi as a Non-Executive Independent Director for a five-year term. The board also approved an increase in authorized capital from Rs. 4.50 crore to Rs. 11.00 crore. The company's 8th Annual General Meeting is scheduled for September 30, 2025, in New Delhi. M/s. Chauhan Pradeep & Associates has been appointed as Secretarial Auditors for a five-year term and as the scrutinizer for the upcoming AGM.
Dr Lalchandani Labs
9.
88
-
9.
88
(-
100.
00
%)
1 Year Returns:
-100.00%
Industry Peers
Dr. Lal Path Labs
1,413.50
(-
0.
18
%)
Vijaya Diagnostic Centre
1,103.70
(-
0.
75
%)
Metropolis Healthcare
481.55
(+
1.
06
%)
Thyrocare Technologies
413.70
(+
0.
30
%)
Nephrocare Health Services
537.25
(-
0.
26
%)
Krsnaa Diagnostics
599.05
(-
0.
17
%)
Suraksha Diagnostic
283.14
(-
0.
88
%)
3B BlackBio DX
1,311.10
(+
0.
94
%)
One Global Service Provider
548.25
(+
1.
83
%)
Sastasundar Ventures
270.95
(+
0.
06
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO